Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




BD Diagnostics Acquires Kiestra and Expands Microbiology Portfolio

By LabMedica International staff writers
Posted on 13 Mar 2012
BD Diagnostics (Franklin Lakes, NJ, USA) has acquired Kiestra (Drachtan, the Netherlands), expanding the company microbiology portfolio to include new automated instrumentation technologies, which will enable it to offer total lab automation solutions to hospitals and laboratories worldwide.

Kiestra Lab Automation BV, which designs, develops, manufactures, markets, and sells lab automation solutions for the microbiology lab, complements BD’s microbiology portfolio of instruments, reagents, and supplies. More...
Kiestra offers two lines of automated solutions: Total Lab Automation (TLA) and Work Cell Automation (WCA). Total Lab Automation is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results. Kiestra’s Work Cell solutions will offer customers a modular and scalable approach to automate their lab within current space and budget constraints.

“We look forward to joining the BD team to expand automation across the entire microbiology and infectious disease testing process,” said Jetze Botma, vice president, microbiology laboratory automation, who served until the acquisition as CEO, KIESTRA Lab Automation. “Together with BD, we now have the opportunity to integrate automation across microbiology informatics, instruments, and consumables for maximum workflow efficiency, and have access to the global arena.”

Kiestra Lab Automation BV, which designs, develops, manufactures, markets, and sells lab automation solutions for the microbiology lab, complements BD’s microbiology portfolio of instruments, reagents, and supplies. Kiestra offers two lines of automated solutions: Total Lab Automation (TLA) and Work Cell Automation (WCA). Total Lab Automation is designed to significantly increase overall microbiology lab productivity, streamline workflow, and shorten the time to results. Kiestra’s Work Cell solutions will offer customers a modular and scalable approach to automate their lab within current space and budget constraints.

“We look forward to joining the BD team to expand automation across the entire microbiology and infectious disease testing process,” said Jetze Botma, vice president, microbiology laboratory automation, who served until the acquisition as CEO, KIESTRA Lab Automation. “Together with BD, we now have the opportunity to integrate automation across microbiology informatics, instruments, and consumables for maximum workflow efficiency, and have access to the global arena.”

BD is a global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery, and production of new drugs and vaccines.

Related Links:

BD Diagnostics
Kiestra



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.